Summit Therapeutics discloses ~$412M cash balance, awards $540K bonuses to CEO/CFO

Summit Therapeutics Inc.

Preliminary unaudited cash, equivalents, and short-term investments ~$412M as of Dec 31, 2024, including $31.8M loan repayment.
CEO Dr. Zanganeh and CFO Manmeet Soni each granted $540K cash bonus for FY2024, payable Q1 2025; no bonus in FY2023.
Base salaries for both officers increase from $600K to $618K, effective February 1, 2025.
Cash balance is preliminary and subject to year-end closing adjustments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.